


**Certification of Substances Department**

**ATTESTATION OF INSPECTION**

Inspected site	FARMSON PHARMACEUTICAL GUJARAT PVT. LTD. 14, G.I.D.C. Industrial Estate, Nandesari Vadodara District India-391 340 Vadodara, Gujarat
Holder of the Certificate of Suitability	FARMSON PHARMACEUTICAL GUJARAT PVT. LTD. 14, G.I.D.C. Industrial Estate, Nandesari Vadodara District India-391 340 Vadodara, Gujarat
References of CEP dossier	CEP 2002-020 / Paracetamol
Inspection dates	22/05/2017 to 24/05/2017
Inspector / Name of organisation	Dr TASI Gergely, OGYEI, NATIONAL INSTITUTE OF PHARMACY AND NUTRITION, HUNGARY Mr TEMLEITNER Arpad, EDQM, COUNCIL OF EUROPE
Scope of the inspection	The inspection focused on the compliance with the information provided in the above-mentioned application for a certificate of suitability, as well as the implementation of a suitable Quality Management System based on the Good Manufacturing Practice as laid down in the EU Rules governing Medicinal Products in the European Union, Volume 4.
Conclusion	The company operates in accordance with the application submitted and the requirements of the Resolution AP-CSP (07) 1.  This attestation is valid only in conjunction with a valid version of a CEP for the dossier mentioned above.

EDQM Inspection Reference number: INSP 2014-006 P02

Strasbourg, 25 August 2017

  
On behalf of the  
Director of EDQM



Certification of Substances Division

## Certificate of suitability No. R1-CEP 2002-020-Rev 07

1 *Name of the substance:*

2 **PARACETAMOL**

3 *Name of holder:*

4 **FARMSON PHARMACEUTICAL GUJARAT PVT. LTD.**

5 14, G.I.D.C. Industrial Estate, Nandesari

6 Vadodara District

7 India-391 340 Vadodara, Gujarat

8 *Site(s) of production:*

9 **SEE ANNEX 1**

10

**THIS CERTIFICATE SUPERSEDES THE PREVIOUS CERTIFICATE**

11

**R1-CEP 2002-020-REV 06**

12 After examination of the information provided on the manufacturing method and subsequent  
13 processes (including purification) for this substance on the site(s) of production listed in annex, we  
14 certify that the quality of the substance is suitably controlled by the current version of the  
15 monograph **PARACETAMOL** no. 49 of the European Pharmacopoeia, current edition including  
16 supplements.

17 In the last steps of the synthesis water is used as solvent.

18 The re-test period of the substance is 66 months if stored in double polyethylene bags or  
19 polyethylene liners placed in polypropylene bags.

20 The holder of the certificate has declared the absence of use of material of human or animal  
21 origin in the manufacture of the substance

22 The submitted dossier must be updated after any significant change that may alter the quality,  
23 safety or efficacy of the substance.

24 Manufacture of the substance shall take place in accordance with the Good Manufacturing Practice  
25 and in accordance with the dossier submitted.

26 Failure to comply with these provisions will render this certificate void.

Address: 7 Allée Kastner, CS 30026

F-67081 Strasbourg (France)

Tel: +33 (0) 3 88 41 30 30 – Fax: +33 (0) 3 88 41 27 71 - e-mail: cep@edqm.eu


Internet: <http://www.edqm.eu>

27 This certificate is renewed from **16 September 2008** according to the provisions of Resolution  
28 AP-CSP (07) 1, and of Directive 2001/83/EC and Directive 2001/82/EC and any subsequent  
29 amendment, and the related guidelines.

30 This certificate has one annex of 1 page.

31 This certificate has:

32 lines.

  
On behalf of the  
Director of EDQM



Strasbourg, 15 June 2015

DECLARATION OF ACCESS *(to be filled in by the certificate holder under their own responsibility)*

**FARMSON PHARMACEUTICAL GUJARAT PVT. LTD.**, as holder of the certificate of suitability

**R1-CEP 2002-020-Rev 07 for Paracetamol**

hereby authorises .....  
*(name of the pharmaceutical company)*

to use the above-mentioned certificate of suitability in support of their application(s) for the following  
Marketing Authorisation(s): *(name of product(s) and marketing number(s), if known)*

The holder also certifies that no significant changes to the operations as described in the CEP dossier  
have been made since the granting of this version of the certificate.

Date and Signature *(of the CEP holder)*:

**Certification of Substances Division**

**Annex 1: Site(s) of production for R1-CEP 2002-020-Rev 07**

**Production of intermediate(s):**

JNP PRODUCTS  
Plot No. 748/1, G.I.D.C. Industrial Estate  
District Bharuch  
India-392 110 Jhagadia, Gujarat

**Production of Paracetamol:**

FARMSON PHARMACEUTICAL GUJARAT PVT. LTD.  
14, G.I.D.C. Industrial Estate, Nandesari  
Vadodara District  
India-391 340 Vadodara, Gujarat

Farmson Analgesics  
28-35 G.I.D.C. Industrial Estate  
Nandesari  
India-391 340 Vadodara, Gujarat